Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

A victory for the Federal Trade Commission, set to conclude Tuesday, could pave the way for an Amazon buying spree. The deal further expands Carlyle's push into asset-based finance.

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

In terms of liquidity and interest, the mean open interest for Exact Sciences options trades today is 1016.57 with a total ...

Exact’s test could compete with Guardant Health’s Shield blood test, which received approval from the Food and Drug Administration in July.

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

The initial results suggest that Exact’s test could be an alternative to others on the market, but the findings come from a ...

The results now are set to go alongside the company’s BLUE-C trial as part of an FDA submission for the cancer detecting ...